• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Learn Why The Bull Case For Agilent Technologies Stock Could Change Following Boardroom Shakeup

    Simply Wall St·09/10/2026 20:20:34
    Listen to the news
    • Agilent Technologies announced multiple updates, including the retirement of long-serving independent chair Koh Boon Hwee, the election of Dow R. Wilson as board chair, the appointment of former Stryker CFO Glenn Boehnlein as director, and the U.S. launch of the FDA-cleared S540MD Slide Scanner alongside the compact Cary 635 FTIR spectrometer.
    • The combination of refreshed board oversight and new digital pathology and FTIR instruments highlights how Agilent Technologies is aligning governance and product development with rising lab automation, diagnostic efficiency, and workflow productivity demands across clinical and analytical customers.
    • The next area of attention is how Agilent Technologies' new board leadership and S540MD digital pathology launch may influence its broader investment narrative.

    Scan beyond Agilent Technologies and see how other lab automation and diagnostic efficiency plays stack up in our hand picked 89 AI infrastructure stocks.

    Agilent Technologies Investment Narrative Recap

    Owning Agilent Technologies means backing a lab tools provider that leans heavily on recurring consumables, software, and services alongside big ticket instruments. The near term story still hangs on how effectively that mix offsets tariff costs and any softness in capital budgets for pharma, chemicals, and research customers. Recent board changes and new product launches do not fundamentally alter those key swing factors. They sit more in the background as governance and portfolio upkeep while the main watchpoints stay the same. Execution on pricing, cost control, and demand from regulated testing markets remains the core near term catalyst.

    The S540MD digital pathology scanner launch is the clearest operational link to the current investment debate. High throughput diagnostics tools directly plug into themes around automation, AI enabled workflows, and higher margin software and services. That matters for a business that already leans on CrossLab and other recurring lines to balance lumpier hardware cycles. The scanner also keeps Agilent Technologies active in competitive clinical workflows where rivals are investing heavily. For you as a shareholder, the question is how quickly such products translate into scale rather than just headlines.

    Yet the more interesting part of the Agilent Technologies story only really comes into focus once you look at ...

    Read the full Agilent Technologies narrative to see the case behind these numbers.

    Agilent Technologies' narrative projects US$9.0b revenue and US$2.2b earnings by 2029. This implies 7.0% yearly revenue growth and an earnings increase of about US$0.8b from US$1.4b today.

    Agilent Technologies' forecasts point to a $174.90 fair value against a $144.75 share price, indicating a 21% upside to its current price that could narrow quickly.

    NYSE:A 1-Year Stock Price Chart
    NYSE:A 1-Year Stock Price Chart

    Exploring Other Perspectives

    Four fair value estimates from the Simply Wall St Community cluster between US$150.54 and US$191.22, so some retail investors see Agilent Technologies as only modestly mispriced while others pencil in a far richer future. Set that against tariff risks, capital spending sensitivity, and fresh board oversight, and you are looking at genuinely diverging viewpoints worth comparing.

    If you want more context around where other investors land on Agilent Technologies, compare the 3 other fair value estimates for Agilent Technologies.

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so trust your own analysis and judgment.

    • A great starting point for your Agilent Technologies research is our analysis highlighting 4 key rewards that could impact your investment decision.
    • See our latest analysis for Agilent Technologies. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Agilent Technologies' overall financial health at a glance.

    Looking For More Investment Ideas Beyond Agilent Technologies?

    Once you have a handle on Agilent Technologies, it can help to line it up against other opportunities that fit your risk tolerance, income needs, or balance sheet preferences. A focused screener lets you filter quickly instead of getting lost in thousands of tickers.

    • If you are hunting for resilient businesses and want to keep a lid on downside risk, start with a 10 resilient stocks with low risk scores that already clear a tight risk filter.
    • Income focused investors who care about cash returns may want to scan 6 dividend fortresses that combine higher yield with a focus on durability.
    • For those who like finding earlier stage opportunities before they are widely followed, the 17 high quality undiscovered gems can highlight smaller companies with stronger fundamentals than their size suggests.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.